Structure Therapeutics financials
$32.69−6.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$118.6M | -$89.4M | $13.7M | -$73.8M | -$70.5M | -$56.3M | -$47.1M | -$45.8M | -$33.3M | -$32.0M | -$31.0M | -$26.1M |
| Net income | -$106.2M | -$76.0M | $33.0M | -$65.7M | -$61.7M | -$46.8M | -$36.5M | -$34.0M | -$26.0M | -$26.0M | -$24.5M | -$23.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.49 | $-0.35 | $0.17 | $-0.37 | $-0.36 | $-0.27 | $-0.21 | $-0.20 | $-0.18 | $-0.19 | $-0.18 | $-0.21 |
| EBITDA | -$118.1M | -$88.8M | $14.2M | -$73.4M | -$70.2M | -$56.0M | -$46.8M | -$45.6M | -$33.1M | -$31.8M | -$30.9M | -$26.1M |
| Operating cash flow | -$120.1M | $15.2M | -$64.4M | -$51.0M | -$54.6M | -$52.2M | -$36.5M | -$19.7M | -$26.4M | -$34.1M | -$21.7M | -$20.6M |
| Free cash flow | -$120.2M | $14.1M | -$65.9M | -$52.6M | -$54.8M | -$52.5M | -$36.5M | -$20.4M | -$26.8M | -$34.2M | -$22.9M | -$21.4M |
| Diluted shares | 218.0M | 217.3M | 190.2M | 175.5M | 172.6M | 172.1M | 172.1M | 171.6M | 148.2M | 139.7M | 139.4M | 114.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $272.6M | $316.2M | $799.6M | $102.9M | $147.0M | $152.1M |
| Short-term investments | $1.07B | $1.14B | $646.6M | $696.1M | $639.5M | $684.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.43B | $1.51B | $1.58B | $832.2M | $816.4M | $866.5M |
| Total liabilities | $71.0M | $61.0M | $67.5M | $62.1M | $44.4M | $41.9M |
| Shareholders' equity | $1.35B | $1.45B | $1.52B | $770.0M | $772.1M | $824.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology